Patent Application for Synthetic Promoters and Circuits in Cancer Cells

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing "Tissue Specific Synthetic Promoters and Circuits and Use Thereof." The application, US20260085102A1, filed on September 11, 2025, describes nucleic acid molecules configured for specific expression in cancer cells, comprising transcription factor binding regions, minimal promoters, and sequences of interest. It also covers related systems, compositions, and methods for treating cancer.

As a published patent application, this document does not impose immediate regulatory obligations or penalties on regulated entities. However, it signifies potential future developments in cancer therapeutics and gene expression technology. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in oncology research and development, should monitor this and similar patent filings for insights into emerging technologies and potential intellectual property landscapes.

Source document (simplified)

← USPTO Patent Applications

TISSUE SPECIFIC SYNTHETIC PROMOTERS AND CIRCUITS AND USE THEREOF

Application US20260085102A1 Kind: A1 Mar 26, 2026

Inventors

Lior NISSIM, Chaja KATZMAN, Tamar AMINOV, Masha ZAITSEV-CHAIKOVSKY, Nir SKALKA, Amit SHRAGA, Konstantin ROZENBERG, Chen SHIMONI, Inbar SHTEINBERG

Abstract

Nucleic acid molecules configured to specifically express a sequence of interest in a cancer cell, comprising: a transcription factor binding region comprising 3-10 repeats of a transcription factor binding site, a minimal promoter and the sequence of interest operatively linked to the transcription factor binding region and minimal promoter, wherein the transcription factor is selected from SOX9, GATA10, TCF7L1, LEF1, MYBL2 and MYB are provided. Nucleic acid molecule systems and compositions comprising the nucleic acid molecules are also provided as are methods of treating cancer.